Grant: Doctoral Research Award - PA: Drug Safety and Effectiveness
University of Ottawa
$105,000.00
Active Pharmacovigilance and Parkinson's Disease: Identifying Vulnerable Populations at Risk of Developing Cancers or Experiencing Negative Cardiovascular Effects
FY 2012-13
Summary
It is well documented that the North American population is aging at a rapid rate and that the incidence of nervous system disorders, specifically Parkinson's disease (PD), will significantly increase in coming years. As such, there is a need to better identify groups of PD patients that are at risk of experiencing severe reactions to their medications.
The objective of my research project is to identify groups of PD patients in North America who are at risk of developing cancers (i.e. prostate cancers and melanomas) or negative cardiovascular outcomes (heart attacks, blood pressure disorders, and cardiac diseases) as a result of taking medications to treat their symptoms. Additionally, I want to identify which medications or classes of medications, if any, are responsible for increasing a PD patient's risk of experiencing these severe reactions.
In order to calculate the risk of severe reactions to medications, I will use quantitative epidemiological methods to analyze de-identified PD patient data from more than 500 North American hospitals. Findings from my study will identify specific medications or classes of medications that increase the risk of cancers and/or development of negative cardiovascular outcomes for certain groups of PD patients. More specifically, I will be able to identify groups of PD patients by age, sex, or place of residence that are at the greatest risk of severe reactions to their medications.
By identifying groups of PD patients at risk of severe reactions to their medications, regulators and health professionals will be able to make informed decisions that will ensure health for all. Additionally, my findings may lead to the implementation of population health interventions targeted at improving specific determinants of health that are associated with poorer health post-diagnosis with PD.
Department
Program
Doctoral Research Award - PA: Drug Safety and Effectiveness
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
272877
Name
Crispo James A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Active Pharmacovigilance and Parkinson's Disease: Identifying Vulnerable Populations at Risk of Developing Cancers or Experiencing Negative Cardiovascular Effects
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Drug Safety and Effectiveness
Keyworddelim
Adverse Drug Reactions (Adrs); Cancers; Cardiovascular Effects; Case Studies; Cohort Studies; Parkinson'S Disease; Patient Safety; Pharmaceuticals; Pharmacovigilance; Secondary Health Databases
Abstract
It is well documented that the North American population is aging at a rapid rate and that the incidence of nervous system disorders, specifically Parkinson's disease (PD), will significantly increase in coming years. As such, there is a need to better identify groups of PD patients that are at risk of experiencing severe reactions to their medications.
The objective of my research project is to identify groups of PD patients in North America who are at risk of developing cancers (i.e. prostate cancers and melanomas) or negative cardiovascular outcomes (heart attacks, blood pressure disorders, and cardiac diseases) as a result of taking medications to treat their symptoms. Additionally, I want to identify which medications or classes of medications, if any, are responsible for increasing a PD patient's risk of experiencing these severe reactions.
In order to calculate the risk of severe reactions to medications, I will use quantitative epidemiological methods to analyze de-identified PD patient data from more than 500 North American hospitals. Findings from my study will identify specific medications or classes of medications that increase the risk of cancers and/or development of negative cardiovascular outcomes for certain groups of PD patients. More specifically, I will be able to identify groups of PD patients by age, sex, or place of residence that are at the greatest risk of severe reactions to their medications.
By identifying groups of PD patients at risk of severe reactions to their medications, regulators and health professionals will be able to make informed decisions that will ensure health for all. Additionally, my findings may lead to the implementation of population health interventions targeted at improving specific determinants of health that are associated with poorer health post-diagnosis with PD.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Crispo, James A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~